olesoxime   Click here for help

GtoPdb Ligand ID: 8542

Synonyms: cholest-4-en-3-one, oxime | TRO-19622 | TRO19622
Compound class: Synthetic organic
Comment: Olesoxime is an investigational cholesterol-like compound with potential as a therapeutic for amyotrophic lateral sclerosis (ALS) [2,4] or spinal muscular atrophy (SMA).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 0
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 32.59
Molecular weight 399.35
XLogP 10.75
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES ON=C1CCC2(C(=C1)CCC1C2CCC2(C1CCC2C(CCCC(C)C)C)C)C
Isomeric SMILES O/N=C\1/CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCCC(C)C)C)C)C
InChI InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3/b28-21-/t19-,22+,23-,24+,25+,26+,27-/m1/s1
InChI Key QNTASHOAVRSLMD-FCARAQADSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 2I clinical trials have been completed in ALS patients, and although the compound was well tolerated it failed to demonstrate a significant increase in survival versus placebo in patients receiving riluzole therapy. Phase 2 trials in SMA, diabetic neuropathy, non-alcoholic steatohepatitis (NASH) and chemotherapy-induced peripheral neuropathy have also been completed.